			Home About us Contact

Refractory Glaucoma (refractory + glaucoma)

Distribution by Scientific Domains

Medical Sciences	100%

Selected Abstracts

Refractory glaucoma , here there be dragons

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Issue 8 2006
FRANZCO, Robert J Casson DPhil
No abstract is available for this article. [source]

Baerveldt glaucoma implants in the management of refractory glaucoma after vitreous surgery

ACTA OPHTHALMOLOGICA, Issue 1 2010
Elisabeth Van Aken
Abstract. Purpose:, To examine the effectiveness and safety of Baerveldt glaucoma implants in eyes with refractory glaucoma following vitrectomy. Methods:, We performed a retrospective study of a non-comparative case series of 30 eyes of 30 patients who had undergone the implantation of a Baerveldt glaucoma device. All eyes (30/30) had a minimum follow-up of 6 months, and 16/30 (53%) had a follow-up of 24 months. Surgical success was defined as intraocular pressure (IOP) < 22 mmHg on the last two follow-up visits with or without glaucoma medication and a decrease in IOP of at least 20% compared to preoperative values with or without glaucoma medication. Results:, The mean IOP before implantation of a Baerveldt glaucoma device was 30 mmHg [± 11.4 mmHg standard deviation (SD)] with maximally tolerated medical therapy. Six months after implantation of the Baerveldt glaucoma device, the mean IOP was 17.3 mmHg (± 6.7 mmHg SD) and the mean number of glaucoma medications had gone down from 3.0 (± 0.4 SD) to 0.3 (± 0.3 SD). Successful outcomes were found in 24 eyes (80%). Small complications occurred in six eyes (20%): transient postoperative hypotony (17%) and tube retraction (3%). Larger complications occurred in another six eyes (20%): corneal decompensation requiring keratoplasty (7%), suprachoroidal haemorrhage (3%) and persistently high IOP (10%). Conclusion:, Baerveldt glaucoma devices are a valid treatment option in eyes with refractory glaucoma after vitreous surgery, although failure occurred in 20% of our patients. Transient complications occurred in 20% and severe complications in another 20%. [source]

Longterm follow-up of diode laser transscleral cyclophotocoagulation in the treatment of refractory glaucoma

ACTA OPHTHALMOLOGICA, Issue 1 2010
Paolo Frezzotti
Abstract. Purpose:, This prospective study was conducted to evaluate the efficacy and safety of transscleral diode laser cyclophotocoagulation (TDLCP) in advanced refractory glaucoma. Methods:, A total of 124 eyes in 121 patients with advanced glaucoma refractory to medical treatment were treated consecutively with TDLCP. Success was defined as final intraocular pressure (IOP) of 5,21 mmHg in eyes with visual acuity (VA) of more than hand movements (HM) and relief of pain in eyes with VA of HM or less, including blind eyes. Results:, Mean patient age was 65.6 ± 17.1 years (range 14,91 years). Mean follow-up was 17 ± 14.6 months (range 3,42 months). Mean pretreatment IOP was 29.9 ± 8.4 mmHg (range 17,58 mmHg) and IOP at last follow-up was 20.8 ± 8 mmHg (range 6,45 mmHg) (p < 0.001). The number of laser applications (mean 9.2 ± 2.8, range 4,15) and maximal laser power (mean 2.01 ± 0.22 mW, range 1.3,3.0 mW) were not associated with lower postoperative IOP. Intraocular pressure of , 21 mmHg was recorded in 63.0% of eyes at the last follow-up visit. Overall, 28 (21.7%) eyes required at least one retreatment. No phthisis bulbi or persistent hypotonia developed. Conclusions:, TDLCP is an effective and safe method for the treatment of advanced refractory glaucoma, although repeated treatments are often necessary. [source]

A new technique for diode laser cyclophotocoagulation: short term results

ACTA OPHTHALMOLOGICA, Issue 2009
M SURIANO
Purpose To evaluate the efficacy of a new technique for diode laser cyclophotocoagulation in refractory glaucoma. Methods A consecutive case series of 8 eyes of 7 Caucasian patients who underwent gonioprism assisted diode laser cyclophotocoagulation (GADC). GADC with a peripheral corneal approach is a new surgical technique that employs a manual gonioprism, iris hooks, ophthalmic operating microscope and an 810 nm laser diode probe usually utilized for retinal photocoagulation Results The mean follow-up time was 5.9 months (range 3 to 11 months). Mean intraocular pressure (IOP) (±SD) was reduced from 24.5±4.3 mmHg to 11.25±1.7 mmHg. The mean number of IOP lowering eye drops (±SD) was reduced from 2.0±0.8 preoperatively to 0.8±0.5 postoperatively. The visual acuity remained unchanged in 7 of 8 eyes (87.5%) and deteriorated in 1 of 8 eyes (12.5%). Early complications included IOP spike in one patient. No major complications were encountered. No eyes required repeat cyclophotocoagulation. Conclusion Gonioprism assisted diode laser cyclophotocoagulation with peripheral corneal approach appears to be an effective and safe surgical treatment of refractory glaucoma and has the advantage of no requiring of new endoscopic devices. [source]

Inadvertent sclerostomy with encysted bleb following trans-scleral contact diode laser cyclophotocoagulation

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Issue 1 2006
Viney Gupta MD
Abstract A 22-year-old woman underwent 360° trans-scleral contact diode laser cyclophotocoagulation for refractory glaucoma. Conjunctival burns and scleral thinning were noticed inferonasally at the last laser application. Intraocular pressure in the first week was normal. Six months later the patient presented with encysted filtering bleb and high intraocular pressure. Ultrasound biomicroscopy revealed a full thickness sclerostomy. This report suggests that inadvertent sclerostomy may present with encysted bleb months after trans-scleral contact diode laser cyclophotocoagulation. [source]